Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Info For
    • Manuscript Submission
      • 1-Minute Consult
      • Commentary
      • Current Drug Therapy
      • Editorial
      • Guidelines to Practice
      • Interpreting Key Trials
      • Letter to the Editor
      • Review
      • Smart Testing
      • Symptoms to Diagnosis
      • The Clinical Picture
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
1-Minute Consult

How should you assess glycemic control if the hemoglobin A1c is inaccurate or uninterpretable?

Wendy O. Henderson, MD, Mary H. Parker, PharmD, FASHP, FCCP, BCPS, BCCP and Bryan C. Batch, MD, MHS
Cleveland Clinic Journal of Medicine February 2021, 88 (2) 81-85; DOI: https://doi.org/10.3949/ccjm.88a.19135
Wendy O. Henderson
Associate Chief of Staff, Ambulatory Care Service, Durham VA Health Care System; Assistant Professor, Department of Medicine, Duke University, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary H. Parker
Acting Chief Medical Officer, VA Mid-Atlantic Health Care Network (VISN6); Clinical Coordinator/Clinical Pharmacy Specialist, Pharmacy and Ambulatory Care, Durham VA Health Care System, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mary.h.parker@gmail.com
Bryan C. Batch
Endocrine Section Chief, Durham VA Health Care System; Associate Professor of Medicine, Duke University Division of Endocrinology, Durham, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. NGSP
    . HbA1c assay interferences. Accessed January 22, 2021. http://www.ngsp.org/interf.asp.
  2. ↵
    1. Radin MS
    . Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med 2014; 29(2):388–394. doi:10.1007/s11606-013-2595-x
    OpenUrlCrossRefPubMed
    1. American Diabetes Association
    . 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care 2020; 43(suppl 1):S14–S31. doi:10.2337/dc20-S002
    OpenUrlAbstract/FREE Full Text
    1. Lacy ME,
    2. Wellenius GA,
    3. Sumner AE, et al
    . Association of sickle cell trait with hemoglobin A1c in African Americans. JAMA 2017; 317(5):507–515. doi:10.1001/jama.2016.21035
    OpenUrlCrossRef
    1. Blendea MC,
    2. Thompson MJ,
    3. Malkani S
    . Diabetes and chronic liver disease: etiology and pitfalls in monitoring. Clin Diabetes 2010: 28(4):139–144. doi:10.2337/diaclin.28.4.139
    OpenUrlFREE Full Text
  3. ↵
    1. Spencer DH,
    2. Grossman BJ,
    3. Scott MG
    . Red cell transfusion decreases hemoglobin A1c in patients with diabetes. Clin Chem 2011; 57(2):344–346. doi:10.1373/clinchem.2010.157321
    OpenUrlFREE Full Text
    1. Fayyaz B,
    2. Rehman HJ,
    3. Minn H
    . Interpretation of hemoglobin A1c in primary care setting. J Community Hosp Intern Med Perspect 2019; 9(1):18–21. doi:10.1080/20009666.2018.1559432
    OpenUrlCrossRef
  4. ↵
    1. Hellman R
    . When are HBA1c values misleading? AACE Clin Case Reports 2016; 2(4):e377–e379. doi:10.4158/EP161209.CO
    OpenUrlCrossRef
  5. ↵
    1. Nathan DM,
    2. Kuenen J,
    3. Borg R,
    4. Zheng H,
    5. Schoenfeld D,
    6. Heine RJ; A1c-Derived Average Glucose Study Group
    . Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31(8):1473–1478. doi:10.2337/dc08-0545
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. American Diabetes Association
    . eAG/A1C conversion calculator. Accessed January 22, 2021. https://professional.diabetes.org/diapro/glucose_calc
  7. ↵
    1. American Diabetes Association
    . 7. Diabetes technology: standards of medical care in diabetes—2020. Diabetes Care 2020; 43(suppl 1): S77–S88. doi:10.2337/dc20-S007
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Moser O,
    2. Pandis M,
    3. Aberer F, et al
    . A head-to-head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: hypoglycaemia remains the weak spot. Diabetes Obes Metab 2019; 21(4):1043–1048. doi:10.1111/dom.13598
    OpenUrlCrossRef
  9. ↵
    1. Lee JE
    . Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol. Ann Pediatr Endocrinol Metab 2015; 20(2):74–78. doi:10.6065/apem.2015.20.2.74
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kunika K,
    2. Itakura M,
    3. Yamashita K
    . Correction of fructosamine value for serum albumin and globulin concentrations. Diabetes Res Clin Pract 1991; 13(1-2):37–44. doi:10.1016/0168-8227(91)90031-8
    OpenUrlCrossRefPubMed
  11. ↵
    1. Danese E,
    2. Montagnana M,
    3. Nouvenne A,
    4. Lippi G
    . Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol 2015; 9(2):169–176. doi:10.1177/1932296814567227
    OpenUrlCrossRefPubMed
  12. ↵
    1. Kang DS,
    2. Park J,
    3. Kim JK,
    4. Yu J
    . Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus. Ann Pediatr Endocrinol Metab 2015; 20(1):21–26. doi:10.6065/apem.2015.20.1.21
    OpenUrlCrossRef
  13. ↵
    1. Koga M,
    2. Murai J,
    3. Morita S,
    4. Saito H,
    5. Kasayama S
    . Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs. type 2 diabetes mellitus. J Diabetes Complications 2013; 27(3):211–213. doi:10.1016/j.jdiacomp.2012.12.001
    OpenUrlCrossRefPubMed
  14. ↵
    1. Buse JB,
    2. Freeman JL,
    3. Edelman SV,
    4. Jovanovic L,
    5. McGill JB
    . Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 2003; 5(3):355–363. doi:10.1089/152091503765691839
    OpenUrlCrossRefPubMed
  15. ↵
    1. Dungan KM
    . 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008; 8(1):9–19. doi:10.1586/14737159.8.1.9
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kalra S
    . Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 2014; 5(2):355–366. doi:10.1007/s13300-014-0089-4
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Cleveland Clinic Journal of Medicine: 88 (2)
Cleveland Clinic Journal of Medicine
Vol. 88, Issue 2
1 Feb 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How should you assess glycemic control if the hemoglobin A1c is inaccurate or uninterpretable?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
How should you assess glycemic control if the hemoglobin A1c is inaccurate or uninterpretable?
Wendy O. Henderson, Mary H. Parker, Bryan C. Batch
Cleveland Clinic Journal of Medicine Feb 2021, 88 (2) 81-85; DOI: 10.3949/ccjm.88a.19135

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
How should you assess glycemic control if the hemoglobin A1c is inaccurate or uninterpretable?
Wendy O. Henderson, Mary H. Parker, Bryan C. Batch
Cleveland Clinic Journal of Medicine Feb 2021, 88 (2) 81-85; DOI: 10.3949/ccjm.88a.19135
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • HEMOGLOBINOPATHIES CAN INTERFERE WITH HEMOGLOBIN A1c
    • ALTERNATIVE METHODS TO ASSESS LONG-TERM GLYCEMIC CONTROL
    • EDUCATING PATIENTS AND PROVIDERS ON ALTERNATIVE TESTS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Does my healthy 65-year-old patient still need the 13-valent pneumococcal conjugate vaccine (PCV13)?
  • When is contrast needed for abdominal and pelvic CT?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Geriatrics
  • Hematology
  • Nephrology
  • Endocrinology
  • Drug Therapy
  • Diabetes

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit
  • Advertise Contact

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • Advertisers
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2021 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire